Skip to main content

Table 4 Summary of EQ5D utility scores included in studies

From: Meta-analysis of health state utility values measured by EuroQol 5-dimensions (EQ5D) questionnaire in Chinese women with breast cancer

Outcome Yang 2020 [20] Li 2019 [23] Ou 2019 [24] Wang 2018 [22] Cheung 2014 [21]
n = 446 n = 608 n = 193 n = 2626 n = 238
EQ-5D-5L Mean ± SD Mean ± SD Mean ± SD Mean (95%CI) Mean ± SD
Mean 0.86 ± 0.19 0.83 ± 0.18 0.92 ± 0.09 (n=182) 0.78 (0.77, 0.79) 0.77 ± 0.163
Stage or TNM stage
Stage/TNM 0 nr nr 0.93 ± 0.06 (n=22) nr nr
Stage/TNM I nr nr 0.94 ± 0.06 (n=48) 0.79 (0.77, 0.81) (n=498) nr
Stage/TNM 0&I nr 0.83 ± 0.17 (n=175) nr nr nr
Stage/TNM II nr 0.86 ± 0.18 (n=142) 0.91 ± 0.10 (n=65) 0.79 (0.78, 0.80) (n=1,234) nr
Stage/TNM III nr 0.82 ± 0.18 (n=218) 0.91 ± 0.12 (n=37) 0.77 (0.76, 0.79) (n=556) nr
Stage/TNM IV nr 0.78 ± 0.22 (n=73) 0.91 ± 0.03 (n=3) 0.69 (0.65, 0.72) (n=224) nr
State
State P 0.81 ± 0.23 (n=125) 0.86 ± 0.17 (n=157) nr nr nr
State S 0.90 ± 0.12 (n=258) 0.85 ± 0.16 (n=245) nr nr nr
State R 0.78 ± 0.31 (n=20) 0.72 ± 0.16 (n=65) nr nr nr
State M 0.74 ± 0.27 (n=43) 0.79 ± 0.23 (n=141) nr nr nr
Time since diagnosis
≤12 months 0.81 (nr) (n=133) 0.81 ±0.18 (n=190) nr nr nr
13-36 months 0.89 (nr) (n=147) 0.84 ±0.18 (n=197) 0.92 ±0.08 (n=66)a nr nr
37-60 months 0.91 (nr) (n=78) 0.85 ± 0.20 (n=112) 0.92 ± 0.09 (n=74)b nr nr
≥ 61 months 0.83 (nr) (n=88) 0.81 ± 0.17 (n=109) 0.94 ± 0.10 (n=27)c
0.89 ± 0.10 (n=25)d
nr nr
Treatment regimen
Chemotherapy nr 0.86 ±0.17 (n=288) 0.91 ±0.10 (n=135) 0.80 (0.78,0.81) (n=689) nr
Surgery & chemotherapy nr 0.71 ±0.15 (n=69) nr 0.79 (0.78,0.80) (n=849)e
0.78 (0.75,0.81) (n=179)f
nr
Concurrent chemoradiotherapy nr 0.65 ±0.14 (n=26) nr 0.76 (0.70,0.82) (n=47) nr
Radiotherapy nr 0.79 ±0.11 (n=14) 0.94 ±0.08 (n=71)g
0.91 ±0.10 (n=108)h
nr nr
Endocrine therapy 0.88 (nr) (n=307) 0.86 ±0.16 (n=73) 0.93 ±0.08 (n=107)i
0.91 ±0.10 (n=79)j
nr nr
  1. TNM = Tumor, Nodes, Metastases. nr=not reported. a reported as <36 months; b reported as 3-6 years; c reported as 7-9 years; d reported as >9 years; e surgery and postoperative chemotherapy, f surgery & neoadjuvant chemotherapy; g partial mastectomy; h total mastectomy; i Tamoxifen, j Aromatose inhibitors.